Search Results for "MenHibrix"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for MenHibrix. Results 1 to 2 of 2 total matches.

In Brief: Meningococcal Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2013  (Issue 1429)
in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix ...
Rates of meningococcal disease are highest in infancy, but until recently no meningococcal vaccine was approved for use in this age group. MenHibrix (GSK), a new conjugate vaccine that protects against Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib), has been approved by the FDA for use in infants ≥6 weeks old and Menveo, a meningococcal vaccine already approved for patients ≥2 years old that protects against serogroups A, C, Y, and W-135, is now approved for use in infants ≥2 months old.SEROGROUPS — Five major serogroups of N. meningitidis, A, B, C,...
Med Lett Drugs Ther. 2013 Nov 11;55(1429):92 |  Show IntroductionHide Introduction

Trumenba: A Serogroup B Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
, and laboratory personnel routinely exposed to isolates of N. meningitidis (MenHibrix is recommended for infants ...
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):5-6 |  Show IntroductionHide Introduction